Immunologic Research

, Volume 66, Issue 6, pp 675–685 | Cite as

Autoimmune vertigo: an update on vestibular disorders associated with autoimmune mechanisms

  • Francesca Yoshie Russo
  • Massimo Ralli
  • Daniele De SetaEmail author
  • Patrizia Mancini
  • Alessandro Lambiase
  • Marco Artico
  • Marco de Vincentiis
  • Antonio Greco


The role of the immune system in mediating cochleovestibular pathologies has received increasing attention in recent years. Autoimmune vertigo may be an invalidating condition and may worsen the quality of life of affected patients, especially in the cases of delayed diagnosis. Since the etiopathogenesis is still not clear, also the treatment is not yet completely delineated. According to the clinical presentation, autoimmune vertigo can present as an isolated disorder or in association with systemic autoimmune diseases. The main feature in autoimmune vertigo is the presence of an abnormal immune response, in either absence or presence of systemic autoimmune disease, directed against delicate components of the inner ear. This may determine a functional or anatomical alteration, with an inflammatory reaction often devastating for hearing and balance. Being the exact pathogenesis unknown, the diagnosis of autoimmune vertigo is based either on clinical criteria or on a positive response to steroids. The earlier the diagnosis is made, the sooner the therapy can be installed, giving a chance to the recovery of inner ear damages. Corticosteroids represent the most effective and universally accepted treatment, even if other immunomodulatory drugs are now having a more extensive use.


  • Vertigo is relatively frequent in autoimmune diseases; however, it is often misdiagnosed or attributed to central nervous system alterations rather to specific inner ear involvement.

  • Vertigo and other audiovestibular symptoms may be the first manifestation of an autoimmune disease and if correctly addressed could significantly contribute to early diagnosis of the underlying autoimmune disease.

  • Early diagnosis of immune-related vertigo can lead to prompt initiation of targeted therapy with elevate chances of preventing irreversible damages to the inner ear.

  • The presence of alternating phases of well-being and disabling symptoms in patients with vertigo should always been considered, as they could suggest an underlying autoimmune condition.


Vertigo Autoimmunity Multiple sclerosis Inner ear Thyroditis Menière disease 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Ruckenstein MJ. Autoimmune inner ear disease. Curr Opin Otolaryngol Head Neck Surg. 2004;12:426–30.Google Scholar
  2. 2.
    Hughes G, Kinney S, Barna B, Calabrese L, Hamid M. Autoimmune reactivity in Menière’s disease: preliminary report. Laryngoscope. 1983;43:410–7.Google Scholar
  3. 3.
    McCabe B. Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol. 1979;88:585–9.Google Scholar
  4. 4.
    Tomiyama S, Harris JP. The endolymphatic sac: its importance in inner ear immune responses. Laryngoscope. 1986;96(6):685–91.Google Scholar
  5. 5.
    Vambutas A, Pathak S. AAO: autoimmune and autoinflammatory (disease) in otology: what is new in immune-mediated hearing loss. Laryngoscope Investig Otolaryngol. 2016;1:110–5.Google Scholar
  6. 6.
    Russo FY, De Seta D, Lahlou G, Borel S, Nguyen Y, Bouccara D, et al. Fluctuating hearing loss in the only hearing ear: Cochlear implantation in the contralateral deaf side. Otolaryngol Head Neck Surg. 2018;1:194599818763137.Google Scholar
  7. 7.
    Ding CR, Xu XD, Wang XW, Jia XH, Cheng X, Liu X, et al. Effect of endolymphatic hydrops on sound transmission in live Guinea pigs measured with a laser Doppler vibrometer. Neural Plast. 2016;2016:8648297.Google Scholar
  8. 8.
    Mancini P, Atturo F, Di Mario A, Portanova G, Ralli M, De Virgilio A, et al. Hearing loss in autoimmune disorders: prevalence and therapeutic options. Autoimmun Rev. 2018;17(7):644–52.Google Scholar
  9. 9.
    Wolfson RJ, Leiberman A. Unilateral deafness with subsequent vertigo. Laryngoscope. 1975;85:1762–6.Google Scholar
  10. 10.
    Nadol JB Jr, Weiss AD, Parker SW. Vertigo of delayed onset after sudden deafness. Ann Otol Rhinol Laryngol. 1975;84:841–6.Google Scholar
  11. 11.
    Schuknecht HF, Suzuka Y, Zimmermann C. Delayed endolymphatic hydrops and its relationship to Meniére's disease. Ann Otol Rhinol Laryngol. 1990;99:843–53.Google Scholar
  12. 12.
    Harris JP, Aframian D. Role of autoimmunity in contralateral delayed endolymphatic hydrops. Am J Otolaryngol. 1994;15:710–6.Google Scholar
  13. 13.
    Morgan AE, Ismail EI, Ashraf B. Intratympanic injections of dexamethasone in delayed endolymphatic hydrops: a prospective clinical study. ORL J Otorhinolaryngol Relat Spec. 2018;80:19–27.Google Scholar
  14. 14.
    Committee on Hearing and Equilibrium: guidelines for the diagnosis and evaluation of therapy inMeniere's disease. Amer Acad Otolaryngol Head Neck Surg Foundation Inc. Otolaryngol Head Neck Surg. 1995;113:176–8.Google Scholar
  15. 15.
    Paparella MM. Pathogenesis of Meniere’s disease and Meniere’s syndrome. Acta Otolaryngol Suppl. 1984;406:10–25.Google Scholar
  16. 16.
    Merchant SN, Adams JC, Nadol JB. Pathophysiology of Meniere’s syndrome: are symptoms caused by endolymphatic hydrops. Otol Neurotol. 2005;26:74–81.Google Scholar
  17. 17.
    Schuknecht HF. Pathology of the ear. 2nd ed. Philadelphia/Baltimore: Lea & Febiger; 1993.Google Scholar
  18. 18.
    Wackym PA, Schuknecht HF, Ward PH, Linthicum FH, Kerner MM, Aframian D, et al. Blinded control study of endolymphatic duct and sac fibrosis in Meniere’s disease. In: Filipo R, Barbara M, editors. Meniere’s disease: perspectives in the 90s. Amsterdam/New York: Kugler Publ; 1994. p. 209–15.Google Scholar
  19. 19.
    Dornhoffer JL, Arenberg IK. Immune mechanisms in Meniere’s syndrome. Otolaryngol Clin N Am. 1997;30:1017–26.Google Scholar
  20. 20.
    Greco A, Gallo A, Fusconi M, Marinelli C, Macri GF, de Vincentiis M. Meniere’s disease might be an autoimmune condition? Autoimmun Rev. 2012;11:731–8.Google Scholar
  21. 21.
    Gazquez I, Soto-Varela A, Aran I, Santos S, Batuecas A, Trinidad G, et al. High prevalence of systemic autoimmune diseases in patients with Meniere’s disease. PLoS One. 2011;6:e26759.Google Scholar
  22. 22.
    Wackym PA, Friberg U, Linthicum FH Jr, Bagger-Sjoback D, Bui HT, Hofman F, et al. Human endolymphatic sac: morphologic evidence of immunologic function. Ann Otol Rhinol Laryngol. 1987;96:276–81.Google Scholar
  23. 23.
    Yoo TJ, Yazawa Y, Tomoda K, Floyd R. Type II collagen-induced autoimmune endolymphatic hydrops in Guinea pig. Science. 1983;113:65–7.Google Scholar
  24. 24.
    Fattori B, Nacci A, Dardano A, Dallan I, Grosso M, Traino C, et al. Possible association between thyroid autoimmunity and Meniere’s disease. Clin Exp Immunol. 2008;152:28–32.Google Scholar
  25. 25.
    Hornibrook J, George P, Spellerberg M, Gourley J. HSP70 antibodies in 80 patients with “clinically certain” Meniere’s disease. Ann Otol Rhinol Laryngol. 2011;120:651–5.Google Scholar
  26. 26.
    Pham BN, Rudic M, Bouccara D, Sterkers O, Belmatoug N, Bébéar JP, et al. Antibodies to myelin protein zero (P0) protein as markers of auto-immune inner ear diseases. Autoimmunity. 2007;40:202–7.Google Scholar
  27. 27.
    Shin SO, Billings PB, Keithley EM, Harris JP. Comparison of anti-head shock protein 70 (anti-hsp70) and anti-68-kDa inner ear protein in the sera of patients with Meniere’s disease. Laryngoscope. 1997;107:222–7.Google Scholar
  28. 28.
    Yoo TJ. Etiopathogenesis of Ménière’s disease: a hypothesis. Ann Otol Rhinol Laryngol. 1984;113:6–12.Google Scholar
  29. 29.
    Suchan M, Kaliarik L, Krempaska S, Koval J. Immune-mediated cochleovestibular disease. Bratisl Lek Listy. 2016;117:87–90.Google Scholar
  30. 30.
    Riente L, Bongiorni F, Nacci A, Migliorini P, Segnini G, Delle Sedie A, et al. Antibodies to inner ear antigens in Meniere’s disease. Clin Exp Immunol. 2004;135:159–63.Google Scholar
  31. 31.
    Brookes G. Circulating immune complexes in Ménière’s disease. Arch Otolaryngol Head Neck Surg. 1986;112:536–40.Google Scholar
  32. 32.
    Kim SH, Kim JY, Lee HJ, Gi M, Kim BG, Choi JY. Autoimmunity as a candidate for the etiopathogenesis of Meniere’s disease: detection of autoimmune reactions and diagnostic biomarker candidate. PLoS One. 2014;9:e111039.Google Scholar
  33. 33.
    Wei NR, Helms J, Giebel W. Immunohistochemical findings in the vestibular ganglion from a patient with Meniere’s disease. Eur Arch Otorhinolaryngol. 1990;247:340–4.Google Scholar
  34. 34.
    Yoo TJ, Stuart JM, Kang AH, Townes AS, Tomoda K, Dixit S. Type II collagen autoimmunity in otosclerosis and Ménière’s disease. Science. 1982;217:1153–5.Google Scholar
  35. 35.
    Nakashima T, Pyykkö I, Arroll MA, Casselbrant ML, Foster CA, Manzoor NF, et al. Meniere’s disease. Nat Rev Dis Primers. 2016;2:16028.Google Scholar
  36. 36.
    Zingler VC, Cnyrim C, Jahn K, Weintz E, Fernbacher J, Frenzel C, et al. Causative factors and epidemiology of bilateral vestibulopathy in 255 patients. Ann Neurol. 2007;61:524–32.Google Scholar
  37. 37.
    Strupp M, Kim JS, Murofushi T, Straumann D, Jen JC, Rosengren SM, et al. Bilateral vestibulopathy: diagnostic criteria consensus document of the Classification Committee of the Bárány Society. J Vestib Res. 2017;27:177–89.Google Scholar
  38. 38.
    Greco A, De Virgilio A, Gallo A, Fusconi M, Ruoppolo G, Turchetta R, et al. Idiopathic bilateral vestibulopathy: an autoimmune disease? Autoimmun Rev. 2014;13:1042–7.Google Scholar
  39. 39.
    Kattah JC. Clinical characteristics and etiology of bilateral vestibular loss in a cohort from Central Illinois. Front Neurol. 2018;9:46.Google Scholar
  40. 40.
    Arbusow V, Strupp M, Dieterich M, Stocker W, Naumann A, Schulz P, et al. Serum antibodies against membraneous labyrinth in patients with “idiopathic” bilateral vestibulopathy. J Neurol. 1998;245:132–6.Google Scholar
  41. 41.
    Agrup C, Keir G, Thompson EJ, Bronstein AM. Systemic autoantibodies against discrete inner ear compartments in bilateral vestibular loss. Neurology. 2005;65:167.Google Scholar
  42. 42.
    Di Stadio A, Ralli M. Systemic lupus erythematosus and hearing disorders: literature review and meta-analysis of clinical and temporal bone findings. J Int Med Res. 2017;45:1470–80.Google Scholar
  43. 43.
    Cogan D. Syndrome of non-syphilitic interstitial keratitis and vestibuloauditory symptoms. Arch Ophthalmol. 1945;33:144–9.Google Scholar
  44. 44.
    Haynes BF, Kaiser-Kupfer MI, Mason P, Fauci AS. Cogan syndrome: studies in thirteen patients, long-term follow-up, and a review of the literature. Medicine. 1980;59:426–41.Google Scholar
  45. 45.
    Cheson BD, Bluming AZ, Alroy J. Cogan’s syndrome: a systemic vasculitis. Am J Med. 1976;60:549–55.Google Scholar
  46. 46.
    Greco A, Gallo A, Fusconi M, Magliulo G, Turchetta R, Marinelli C, et al. Cogan’s syndrome: an autoimmune inner ear disease. Autoimmun Rev. 2013;12:396–400.Google Scholar
  47. 47.
    Brinkman CJ, Broekhuyse RM. Cell-mediated immunity after retinal detachment as determined by lymphocyte stimulation. Am J Ophthalmol. 1978;86:260–5.Google Scholar
  48. 48.
    Schuknecht HF. Ear pathology in autoimmune diseases. Adv Otorhinolaryngol. 1991;46:50–70.Google Scholar
  49. 49.
    Hughes GB, Kinney SE, Barna BP, Tomsak RL, Calabrese LH. Autoimmune reactivity in Cogan’s syndrome: a preliminary report. Arch Otolaryngol Head Neck Surg. 1983;91:24–32.Google Scholar
  50. 50.
    Peeters GJ, Cremers CW, Pinckers AJ, Hoefnagels WHL. Atypical Cogan’s syndrome: an autoimmune disease? Ann Otol Rhinol Laryngol. 1986;95:173–5.Google Scholar
  51. 51.
    Lunardi C, Bason C, Leandri M, Navone R, Lestani M, Millo E, et al. Autoantibodies to inner ear and endothelial antigens in Cogan’s syndrome. Lancet. 2002;360:915–21.Google Scholar
  52. 52.
    Greco A, De Virgilio A, Ralli M, Ciofalo A, Mancini P, Attanasio G, et al. Lambiase Behçet's disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018: S1568–9972(18)30079-X;17:567–75.Google Scholar
  53. 53.
    Zeidan MJ, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P. Behçet’s disease physiopathology: a contemporary review. Auto Immun Highlights. 2016;7:4.Google Scholar
  54. 54.
    Gemignani G, Berrettini S, Bruschini P, Sellari-Franceschini S, Fusari P, Piragine F, et al. Hearing and vestibular disturbances in Behçet’s syndrome. Ann Otol Rhinol Laryngol. 1991;100:459–63.Google Scholar
  55. 55.
    Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain. 1999;122:2171–82.Google Scholar
  56. 56.
    Pollak L, Luxon LM, Haskard DO. Labyrinthine involvement in Behçet’s syndrome. J Laryngol Otol. 2001;115:522–9.Google Scholar
  57. 57.
    Kulahli I, Balci K, Koseoglu E, Yuce I, Cagli S, Senturk M. Audio-vestibular disturbances in Behçet’s patients: report of 62 cases. Hear Res. 2005;203:28–31.Google Scholar
  58. 58.
    Kocer N, Islak C, Siva A, Saip S, Akman C, Kantarci O, et al. CNS involvement in neuro-Behçet syndrome: an MR study. Am J Neuroradiol. 1999;20:1015–24.Google Scholar
  59. 59.
    Pay S, Simsek I, Erdem H, Dinc A. Immunopathogenesis of Behçet’s disease with special emphasize to the possible role of antigen presenting cells. Rheumatol Int. 2007;27:417–24.Google Scholar
  60. 60.
    Kulaber A, Tugal-Tutkun I, Sibel P, Akman-Demir G, Kaneko F, Gul A, et al. Proinflammatory cellular immune response in Behçet’s disease. Rheumatol Int. 2007;27:1113–8.Google Scholar
  61. 61.
    Vitale A, Rigante D, Lopalco G, Selmi C, Galeazzi M, Iannone F, et al. Interleukin-1 inhibition in Behçet’s disease. Isr Med Assoc J. 2016;18(3-4):171–6. ReviewGoogle Scholar
  62. 62.
    Shi T, Lv W, Zhang L, et al. Association of HLA-DR4/HLA-DRB1∗04 with Vogt-Koyanagi-Harada disease: a systematic review and meta-analysis. Sci Rep. 2014;4:6887.Google Scholar
  63. 63.
    Ng JY, Luk FO, Lai TY, et al. Influence of molecular genetics in Vogt-Koyanagi-Harada disease. J Ophthalmic Inflamm Infect. 2014;4:20.Google Scholar
  64. 64.
    Perry HD, Font RL. Clinical and histopathologic observations in severe Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1977;83:242–54.Google Scholar
  65. 65.
    Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007;114:606–14.Google Scholar
  66. 66.
    Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39:265–92.Google Scholar
  67. 67.
    Greco A, Fusconi M, Gallo A, Turchetta R, Marinelli C, Macri GF, et al. Vogt-Koyanagi-Harada syndrome. Autoimmun Rev. 2013;12:1033–8.Google Scholar
  68. 68.
    Liu B, Deng T, Zhu L, Zhong J. Association of human leukocyte antigen (HLA)-DQ and HLA-DQA1/DQB1 alleles with Vogt-Koyanagi-Harada disease: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e9914.Google Scholar
  69. 69.
    Du L, Yang P, Hou S, et al. Association of the CTLA-4 gene with Vogt-Koyanagi-Harada syndrome. Clin Immunol. 2008;127:43–8.Google Scholar
  70. 70.
    Lacomba MS, Martin CM, Chamond RR, Galera JM, Omar M, Estevez EC. Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis. Arch Ophthalmol. 2000;118:768–72.Google Scholar
  71. 71.
    Sheereen A, Gaafar A, Iqneibi A, Eldali A, Tabbara KF, Adra C, et al. A study of KIR genes and HLA-C in Vogt-Koyanagi-Harada disease in Saudi Arabia. Mol Vis. 2011;17:3523–8.Google Scholar
  72. 72.
    Levinson RD, Okada AA, Ashouri E, Keino H, Rajalingam R. Killer cell immunoglobulin-like receptor gene-cluster 3DS1-2DL5-2DS1-2DS5 predisposes susceptibility to Vogt-Koyanagi-Harada syndrome in Japanese individuals. Hum Immunol. 2010;71:192–4.Google Scholar
  73. 73.
    Mittal KK. Immunobiology of the human major histocompatibility complex: association of HLA antigens with disease. Acta Anthropogenet. 1984;8:245–68.Google Scholar
  74. 74.
    Peng Z, Jiang S, Wu M, Zhou X, Wang Q. Expression and role of interleukin-9 in Vogt-Koyanagi-Harada disease. Mol Vis. 2017;23:538–47. eCollection 2017Google Scholar
  75. 75.
    Pelosi S, Chandrasekhar SS. Intratympanic steroid use for hearing salvage in Vogt-Koyanagi-Harada syndrome. Ear Nose Throat J. 2011;90:574–7.Google Scholar
  76. 76.
    Berrih-Aknin S. Myasthenia gravis: paradox versus paradigm in autoimmunity. J Autoimmun. 2014;52:1–28.Google Scholar
  77. 77.
    Lin C, Lin SW, Weng SF, Lin YS. Risk of sudden sensorineural hearing loss in patients with systemic lupus erythematosus: a population-based cohort study. Audiol Neurootol. 2013;18:95–100.Google Scholar
  78. 78.
    Lam NC, Ghetu MV, Bieniek ML. Systemic lupus erythematosus: primary care approach to diagnosis and management. Am Fam Physician. 2016;94:284–94.Google Scholar
  79. 79.
    McCarty DJ, Manzi S, Medsger TA Jr, et al. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum. 1995;38:1260–70.Google Scholar
  80. 80.
    Karatas E, Onat AM, Durucu C, Baglam T, Kanlikama M, Altunoren O, et al. Audiovestibular disturbance in patients with systemic lupus erythematosus. Otolaryngol Head Neck Surg. 2007;136:82–6.Google Scholar
  81. 81.
    Batuecas-Caletrío A, del Pino-Montes J, Cordero-Civantos C, Calle-Cabanillas MI, Lopez-Escamez JA. Hearing and vestibular disorders in patients with systemic lupus erythematosus. Lupus. 2013;22:437–42.Google Scholar
  82. 82.
    Weckerle CE, Franek BS, Kelly JA, Kumabe M, Mikolaitis RA, Green SL, et al. Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011;63:1044–53.Google Scholar
  83. 83.
    Riggs JM, Hanna RN, Rajan B, Zerrouki K, Karnell JL, Sagar D, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5:e000261.Google Scholar
  84. 84.
    Wu M, Yang J, Li X, et al. The role of γδ T cells in systemic lupus erythematosus. J Immunol Res. 2016;2016:2932531.Google Scholar
  85. 85.
    Fukushima N, Fukushima H, Cureoglu S, Schachern PA, Paparella MM. Hearing loss associated with systemic lupus erythematosus: temporal bone histo-pathology. Otol Neurotol. 2006;27:127–8.Google Scholar
  86. 86.
    Kariya S, Hızlı O, Kaya S, et al. Histopathologic findings in peripheral vestibular system from patients with systemic lupus erythematosus: a human temporal bone study. Otol Neurotol. 2015;36:1702–7.Google Scholar
  87. 87.
    McCabe BF. Autoimmune inner ear disease: results of therapy. Adv Otorhinolaryngol. 1991;46:78–81.Google Scholar
  88. 88.
    Dasgupta S. Therapeutic interventions of tissue specific autoimmune onset in systemic lupus erythematosus. Mini-Rev Med Chem. 2016;16:1.Google Scholar
  89. 89.
    Petri M. Systemic lupus erythematosus and related diseases: clinical features. In: Rose NR, Mackay IR, editors. The autoimmune dis-eases. 4th ed. St Louis: Elsevier Academic Press; 2006. p. 351–6.Google Scholar
  90. 90.
    Relle M, Weinmann-Menke J, Scorletti E, Cavagna L, Schwarting A. Genetics and novel aspects of therapies in systemic lupus erythematosus. Autoimmun Rev. 2015;14:1005–18.Google Scholar
  91. 91.
    Greco A, De Virgilio A, Gallo A, Fusconi M, Turchetta R, Tombolini M, et al. Susac’s syndrome--pathogenesis, clinical variants and treatment approaches. Autoimmun Rev. 2014;13:814–21.Google Scholar
  92. 92.
    Gross M, Banin E, Eliashar R, Ben-Hur T. Susac syndrome. Otol Neurotol. 2004;25:470–3.Google Scholar
  93. 93.
    Susac JO. Susac’s syndrome: the triad of microangiopathy of the brain and retina with hearing loss in young women. Neurology. 1944;44:591–3.Google Scholar
  94. 94.
    Martinet N, Fardeau C, Adam R, Bodaghi B, Papo T, Piette JC, et al. Fluorescein and indocyanine green angiographies in Susac syndrome. Retina. 2007;27:1238–42.Google Scholar
  95. 95.
    Bucciarelli S, Cervera R, Martinez M, Latorre X, Font J. Susac’s syndrome or catastrophic antiphospholipid syndrome. Lupus. 2004;3:607–8.Google Scholar
  96. 96.
    Petty GW, Engel AG, Younge BR, Duffy J, Janagihara T, Lucchinetti CF, et al. Retinocochleocerebral vasculopathy. Medicine (Baltimore). 1998;77:12–40.Google Scholar
  97. 97.
    Saw VP, Canty PA, Green CM, Briggs RJ, Cremer PD, Harrisberg B, et al. Susac syndrome: microangiopathy of the retina, cochlea and brain. Clin Exp Ophthalmol. 2000;28:373–81.Google Scholar
  98. 98.
    Magro CM, Poe JC, Lubow M, Susac JO. Susac syndrome: an organ-specific autoim-mune endotheliopathy syndrome associated with anti-endothelial cell antibodies. Am J Clin Pathol. 2011;136:903–12.Google Scholar
  99. 99.
    Jarius S, Neumayer B, Wandinger KP, Hartmann M, Wildemann B. Anti-endothelial serum antibodies in a patient with Susac’s syndrome. J Neurol Sci. 2009;285:259–61.Google Scholar
  100. 100.
    Magro CM, Ross P, Marsh CB, Marsh JN, Allen JN, Liff D, et al. The role of anti-endothelial cell antibody-mediated microvascular injury in the evolution of pulmonary fibrosis in the setting of collagen vascular disease. Am J Clin Pathol. 2007;127:237–47.Google Scholar
  101. 101.
    Servettaz A, Guilpain A, Camoin L, Mayeux P, Broussard C, Tamby MC, et al. Identification of target antigens of antiendothelial cell antibodies in healthy individuals: a proteomic approach. Proteomics. 2008;8:1000–8.Google Scholar
  102. 102.
    Ayache D, Plouin-Gaudon I, Bakouche P, Elbaz P, Gout O. Microangiopathy of the inner ear, retina, and brain (Susac syndrome): report of a case. Arch Otolaryngol Head Neck Surg. 2000;126:82–4.Google Scholar
  103. 103.
    Petty GW, Matteson EL, Younge BR, McDonald TJ, Wood CP. Recurrence of Susac syndrome (retinocochleocerebral vasculopathy) after remission of 18 years. Mayo Clin Proc. 2001;76:958–60.Google Scholar
  104. 104.
    García-Carrasco M, Jiménez-Hernández C, Jiménez-Hernández M, Voorduin-Ramos S, Mendoza-Pinto C, Ramos-Alvarez G, et al. Susac’s syndrome: an update. Autoimmun Rev. 2011;10:548–52.Google Scholar
  105. 105.
    García-Carrasco M, Mendoza-Pinto C, Cervera R. Diagnosis and classification of Susac syndrome. Autoimmun Rev. 2014;13:347–50.Google Scholar
  106. 106.
    Fox RJ, Costello F, Judkins AR, Galetta SL, Maguire ML, Leonard B, et al. Treatment of Susac syndrome with gamma globulin and corticosteroids. J Neurol Sci. 2006;251:17–22.Google Scholar
  107. 107.
    Milo R, Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev. 2014;13:518–24.Google Scholar
  108. 108.
    Burina A, Sinanović O, Smajlović D, Vidović M, Brkić F. Some aspects of balance disorder in patients with multiple sclerosis. Bosn J Basic Med Sci. 2008;8:80–5.Google Scholar
  109. 109.
    Pula JH, Newman-Toker DE, Kattah JC. Multiple sclerosis as a cause of the acute vestibular syndrome. J Neurol. 2013;260:1649–54.Google Scholar
  110. 110.
    Tarnutzer AA, Berkowitz AL, Robinson KA, Hsieh YH, Newman-Toker DE. Does my dizzy patient have a stroke? A systematic review of bedside diagnosis in acute vestibular syndrome. CMAJ. 2011;183:E571–92.Google Scholar
  111. 111.
    Commins DJ, Chen JM. Multiple sclerosis: a consideration in acute cranial nerve palsies. Am J Otol. 1997;18:590–5.Google Scholar
  112. 112.
    Frohman EM, Zhang H, Dewey RB, Hawker KS, Racke MK, Frohman TC. Vertigo in MS: utility of positional and particle repositioning maneuvers. Neurology. 2000;55:1566–9.Google Scholar
  113. 113.
    Anagnostou E, Mandellos D, Limbitaki G, Papadimitriou A, Anastasopoulos D. Positional nystagmus and vertigo due to a solitary brachium conjunctivum plaque. J Neurol Neurosurg Psychiatry. 2006;77:790–2.Google Scholar
  114. 114.
    Anagnostou E, Varaki K, Anastasopoulos D. A minute demyelinating lesion causing acute positional vertigo. J Neurol Sci. 2008;266:187–9.Google Scholar
  115. 115.
    Degirmenci E, Bir LS, Ardic FN. Clinical and electronystagmographical evaluation of vestibular symptoms in relapsing remitting multiple sclerosis. Neurol Res. 2010;32:986–91.Google Scholar
  116. 116.
    Hellmann MA, Steiner I, Mosberg-Galili R. Sudden sensorineural hearing loss in multiple sclerosis: clinical course and possible pathogenesis. Acta Neurol Scand. 2011;124:245–59.Google Scholar
  117. 117.
    Di Stadio A, Dipietro L, Ralli M, Meneghello F, Minni A, Greco A, et al. Sudden hearing loss as an early detector of multiple sclerosis: a systematic review. Eur Rev Med Pharmacol Sci. 2018;22(14):4611–24.Google Scholar
  118. 118.
    Di Stadio A, Ralli M. Inner ear involvement in multiple sclerosis: an underestimated condition? Mult Scler. 2018;1:1352458518750010.Google Scholar
  119. 119.
    Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev. 2017;16:658–65.Google Scholar
  120. 120.
    McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42:252–65.Google Scholar
  121. 121.
    Weetman AP. Determinants of autoimmune thyroid disease. Nat Immunol. 2001;2:76970. Scholar
  122. 122.
    De Leo S, Pearce EN. Autoimmune thyroid disease during pregnancy. Lancet Diabetes Endocrinol. 2017;12:S2213–8587(17)30402-3.Google Scholar
  123. 123.
    Yoo TJ, Yazawa Y. Immunology of cochlear and vestibular disorders. In: Luxon L, Furman JM, Martini A, Stephens D, editors. Audiological medicine: clinical aspect of hearing and balance. London: Martin Dunitz-Taylor and Francis Group; 2003. p. 61–87.Google Scholar
  124. 124.
    Tamura T. Studies on the correlation between thyroid function and Meniere’s syndrome. Nippon Jibiinkoka Gakkai Kaiho. 1964;67:1434–68.Google Scholar
  125. 125.
    Brenner M, Hoistad DL, Hain TC. Prevalence of thyroid dysfunction in patients with Meniere’s disease. Arch Otolaryngol Head Neck Surg. 2004;130:226–8.Google Scholar
  126. 126.
    Fattori B, Nacci A, Dardano A, Dallan I, Grosso M, Traino C, et al. Possible association between thyroid autoimmunity and Ménière’s disease. Clin Exp Immunol. 2008;152:28–32.Google Scholar
  127. 127.
    Chiarella G, Tognini S, Nacci A, Sieli R, Costante G, Petrolo C, et al. Vestibular disorders in euthyroid patients with Hashimoto’s thyroiditis: role of thyroid autoimmunity. Clin Endocrinol. 2014;81:600–5.Google Scholar
  128. 128.
    Modugno GC, Pirodda A, Ferri GG, Montana R, Rasciti L, Ceroni AR. A relationship between autoimmune thyroiditis and benign paroxysmal positional vertigo? Med Hypotheses. 2000;54:614–5.Google Scholar
  129. 129.
    Papi G, Corsello SM, Milite MT, Zanni M, Ciardullo AV, Donato CDI, et al. Association between benign paroxysmal positional vertigo and auto-immune chronic thyroiditis. Clin Endocrinol. 2009;70:169–70.Google Scholar
  130. 130.
    Sari K, Yildirim T, Borekci H, Akin I, Aydin R, Ozkiris M. The relationship between benign paroxysmal positional vertigo and thyroid autoimmunity. Acta Otolaryngol. 2015;135:754–7.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Francesca Yoshie Russo
    • 1
  • Massimo Ralli
    • 1
  • Daniele De Seta
    • 2
    Email author
  • Patrizia Mancini
    • 1
  • Alessandro Lambiase
    • 1
  • Marco Artico
    • 1
  • Marco de Vincentiis
    • 2
  • Antonio Greco
    • 1
  1. 1.Department of Sense OrgansSapienza University of RomeRomeItaly
  2. 2.Department of Oral and Maxillo-facial SurgerySapienza University of RomeRomeItaly

Personalised recommendations